Citigroup’s Ascendis Pharma A/S ASND Stock Holding History

Citigroup’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,000	Closed	-$2.74M	–	5721
2026 Q1	$2.74M	Sell	12,000 -63,900	-84%	-$14.3M	﹤0.01%	2449
2025 Q4	$16.2M	Buy	+75,900	New	+$15.7M	0.01%	1224
2024 Q3	–	Sell	-12,500	Closed	-$1.7M	–	5674
2024 Q2	$1.7M	Sell	12,500 -12,300	-50%	-$1.67M	﹤0.01%	2476
2024 Q1	$3.75M	Sell	24,800 -3,400	-12%	-$485K	﹤0.01%	1930
2023 Q4	$3.55M	Buy	28,200 +3,200	+13%	+$319K	﹤0.01%	1824
2023 Q3	$2.34M	Hold	25,000	–	–	﹤0.01%	1889
2023 Q2	$2.23M	Hold	25,000	–	–	﹤0.01%	2100
2023 Q1	$2.68M	Buy	25,000 +800	+3%	+$91.5K	﹤0.01%	1828
2022 Q4	$2.96M	Buy	+24,200	New	+$2.81M	﹤0.01%	1781

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Citigroup's ASND Position: Q2 2026 in Review

Citigroup reduced its Ascendis Pharma A/S (ASND) stake by 3.4% in Q2 2026, selling an estimated $235K and leaving 28,693 shares worth $7.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Citigroup first reported a position in ASND in Q1 2015 and has held it in 35 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Citigroup held 28,693 shares of Ascendis Pharma A/S worth $7.65M as of Q2 2026.
Citigroup sold 1,008 Ascendis Pharma A/S shares in Q2 2026, an estimated $235K.
Ascendis Pharma A/S made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1802 holding.
Citigroup first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 35 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.